Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

Selected as best IPO in 2019

FluoGuide won the 2019 share price development award in the micro-cap category and also received the honorary quality award (Affärsvärlden’s IPO Guide).

FluoGuide appoints Henrik Moltke as Chief Financial Officer

Press release


September 21, 2020

Copenhagen, 21 September 2020 – FluoGuide A/S (“FluoGuide” or “the Company”) today announces the appointment of Henrik Moltke as Chief Financial Officer (CFO). Henrik Moltke will begin his employment in December 2020.

FluoGuide is strengthen its partnering, financing and other commercial activities to take full advantages of the upcoming results of the ongoing clinical phase I/II trial, testing FG001 in guiding surgical treatment of high grade glioma (including glioblastoma).

Henrik Moltke, who will be part of FluoGuide’s management team, brings more than 30 years of experience from life sciences and health care sectors, where he has held roles such as CFO and Senior Vice President. The primary focus in his previous career has been in venture financing, including IPOs as well as follow on capital increases in the public markets, investor relations, business development, finance planning and strategic development. Henrik Moltke will begin his employment in December 2020.

“We look very much forward to welcoming Henrik to our team. With a CFO, and one with Henriks calibre, we will be able to accelerate our commercial activites hand-in-hand with developing FG001 towards broad clinical use to the benefit of patients with aggressive brain cancer”, says Morten Albrechtsen, CEO of FluoGuide A/S.

“I look forward to joining FluoGuide’s team and contribute to maturing the company to become a leader in guided oncology surgery”, says Henrik Moltke.